Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07148505 · ClinicalTrials.gov registry record
A Study of Real-world Outcomes Among Patients Treated With Ribociclib
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 373
- Enrollment target
NCT07148505 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 373 participants.
The verdict
NCT07148505 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 373 participants
- Enrollment target
Study Summary
The main aim of the study was to evaluate the real-world tolerability and safety of ribociclib as a first-line (1L) treatment among adults with hormone receptor-positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC). This study used data from the Flatiron Health Research Database (FHRD). The FHRD is a longitudinal database derived from electronic health records (EHRs) and other real-world data (RWD) sources from cancer care providers across the United States. The dataset generated for this study included de-identified patient-level data for eligible individuals between 1 January 2015 up to the data cutoff date, 30 November 2022.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 373 participants |
| Start Date | 2024-04-24 |
| Est. Completion | 2024-11-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07148505
The ClinicalTrials.gov registry entry for NCT07148505 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 373 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07148505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07148505 about?
NCT07148505 is a clinical study titled "A Study of Real-world Outcomes Among Patients Treated With Ribociclib". The main aim of the study was to evaluate the real-world tolerability and safety of ribociclib as a first-line (1L) treatment among adults with hormone receptor-positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC). This study used data from the Flati...
What is the current status of trial NCT07148505?
This trial is currently completed. The enrollment target is 373 participants. The study started on 2024-04-24. Estimated completion is 2024-11-07.
Who is sponsoring clinical trial NCT07148505?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.